| Document |
Document Title |
|
WO/2024/112663A1 |
A deuterated compound is disclosed. A method of controlling various diseases by administration of the deuterated compound is disclosed.
|
|
WO/2024/111564A1 |
The present invention addresses the problem of providing a medicine produced by combining a liposome composition having topotecan or a salt thereof encapsulated therein with a DNA damage repair inhibitor. According to the present inventi...
|
|
WO/2024/111633A1 |
The present invention addresses the problem of providing the induction of antibodies against a target protein using a peptide as an antigen. The present invention relates to a method for preparing a partial peptide that is from within ...
|
|
WO/2024/111609A1 |
The purpose of the present invention is to addresses the problem of providing a new combination therapy for improving the therapeutic effect of a KRAS inhibitor against KRAS mutant cancer. Provided is a therapeutic agent for KRAS mutan...
|
|
WO/2024/110863A1 |
The present disclosure relates to a process for preparing ((1R,2S,4R)-4-((5-(4-((R)-7- chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene
-2-carbonyl)pyrimidin-4- yl)amino)-2-hydroxycyclopentyl)methyl sulfamate and to novel int...
|
|
WO/2024/109952A1 |
Provided is a non-covalent dimer cation of the present application, which is a cation as shown in the drawing of the abstract, a tautomer thereof, or a stereoisomer thereof. Provided is a salt of the present application, comprising a cat...
|
|
WO/2024/110381A1 |
It is provided an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them; a lipid nanoparticle comprising the ionizable lipid, particularly, as an encapsulation agent, optionall...
|
|
WO/2024/109671A1 |
Disclosed are Cas9 protein, variants or homologues thereof-specific PROTAC degrader(s) of Formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, or a polymorph thereof, composition comprising the same, and uses thereof. The sai...
|
|
WO/2022/233625A3 |
Compositions and methods that use a combination of NARH and NR to produce intracellular NAD+/NADH. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions c...
|
|
WO/2024/111590A1 |
The present invention improves the medicinal effect of a Ras inhibitor peptide when being administered to a living body, by improving the solubility of the Ras inhibitor peptide to an aqueous solution. This composition contains: a cyclic...
|
|
WO/2024/108263A1 |
The present disclosure relates to a method of treating, preventing or delaying an age- related condition or pathology in a mammal using extracellular vesicles (EVs) derived from a young mammal.
|
|
WO/2024/111529A1 |
This agent for increasing brain plasmalogen contains a compound represented by formula (I), a racemic body thereof, or a salt of those. [In formula (I), X represents a carbon atom or an oxygen atom, R1 represents a saturated aliphatic hy...
|
|
WO/2024/111626A1 |
The present invention provides a thiazole derivative that has an ALK5 inhibitory action and that is represented by formula (1) (refer to the description with respect to R1, R2, and Z in the formula), or a pharmaceutically acceptable salt...
|
|
WO/2024/112775A1 |
Compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation ...
|
|
WO/2024/106205A1 |
This biological clock regulator contains, as an active ingredient, at least one among bergamot oil, geranium oil, cedarwood virginia oil, citral, and β-caryophyllene, and advances the phase of the expression rhythm of a clock gene.
|
|
WO/2024/106545A1 |
The present invention addresses the problem of providing a novel double-stranded oligonucleotide complex capable of generating an excellent antisense effect in the central nervous system when intrathecally administered. Provided is a c...
|
|
WO/2024/105922A1 |
The present invention provides a composition for anti-obesity, body fat reduction or fat metabolism promotion uses, which contains black ginger as an active ingredient, and also contains hot pepper, an imidazole peptide, and at least one...
|
|
WO/2024/105268A1 |
The present invention relates to a donepezil and a derivative or a pharmaceutically acceptable salt and/or solvate thereof new daily low dosage regimens for the prevention and/or the treatment of a compulsive disorder, notably an eating ...
|
|
WO/2024/107096A1 |
This disclosure provides treprostinil compositions and its use thereof.
|
|
WO/2024/105410A2 |
There is described a compound comprising a sequence of at least 3 amino acids wherein the sequence of 3 amino acids comprises the sequence Ser-Arg-Ala; and variants and derivatives thereof; provided that the amino acid is not: His-Lys-Se...
|
|
WO/2024/106448A1 |
The nucleic acid construct according to the present invention has such a structure that a protein can be expressed by the occurrence of at least two times of a recombinant reaction by single-strand annealing (SSA), is useful for the diag...
|
|
WO/2024/105529A1 |
The present invention relates generally to methods for disbudding livestock using a non-steroidal anti-inflammatory drug (NSAID) while causing little to no pain to the animal. In contrast to traditional livestock disbudding methods, the ...
|
|
WO/2024/106171A1 |
The present invention provides a novel cell culture method and a method for producing a culture supernatant. The present invention provides a method having a step for culturing animal cells in a medium containing a glucose concentratio...
|
|
WO/2024/106501A1 |
[Problem] To provide an oral agent capable of maintaining the health of mammary tissue. [Solution] This agent for maintaining the health of mammary tissue is characterized by containing GABA as an active ingredient. By using GABA in comb...
|
|
WO/2024/105423A1 |
The present invention relates to a donepezil and a derivative or a pharmaceutically acceptable salt and/or solvate thereof new daily low dosage regimens for the prevention and/or the treatment of a compulsive disorder, notably an eating ...
|
|
WO/2024/102177A1 |
Disclosed herein are methods of treating brain cancer in a subject, such as glioblastoma, comprising administering inhibitors of synaptic signaling to the subject.
|
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/102675A1 |
Pharmaceutical compositions of anti-TSLP-R antibodies, and uses thereof, are provided herein. The pharmaceutical compositions can comprise for example, an anti-TSLP- R antibody, or antigen-binding fragment thereof, a pharmaceutically acc...
|
|
WO/2024/102744A1 |
A method for promoting sleep quality in a subject is disclosed, involving the administration of an effective amount of a formulation comprising two or more phytoestrogen compounds or their analogues that selectively bind to estrogen rece...
|
|
WO/2024/101937A1 |
The present invention relates to a formulation capable of inhibiting the early release of a specific PRS inhibitor and has the effect of preventing the side effects of nausea or vomiting, which may occur when too much of an active ingred...
|
|
WO/2024/101345A1 |
Provided is an agent containing an RGMa inhibition substance, the agent being for suppressing accumulation of abnormal protein aggregates or for inhibiting uptake of abnormal proteins by nerve cells, particularly for preventing or treati...
|
|
WO/2024/102956A1 |
Conjugates comprising a fibroblast activation protein alpha (FAPα)-targeted ligand, a bifunctional or trifunctional linker, and an imaging or therapeutic agent; compositions comprising the conjugates; and methods of use in the imaging a...
|
|
WO/2024/100396A1 |
An oral lozenge. The oral lozenge comprises from 0.02 to 0.5% w/w chlorhexidine or a salt thereof and from 2 to 80% w/w polyol. The polyol comprises xylitol, erythritol or maltitol.
|
|
WO/2024/101406A1 |
The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) or liver cancer, the agent containing a material for inhibiting the expression or f...
|
|
WO/2024/099886A1 |
The present disclosure generally relates to compositions and methods to reduce the biological age and/ or reduce the rate of increase of the biological age of an adult animal. More specifically, the present disclosure relates to administ...
|
|
WO/2024/099951A1 |
The present invention relates to a polypeptide for use as a metal-binder, a protein comprising said polypeptide, a nucleic acid molecule encoding said polypeptide or protein, an expression vector comprising the nucleic acid molecule, a r...
|
|
WO/2024/101336A1 |
One embodiment of the present invention provides a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing the splicing anomalies that are a factor in the onset or progression of disease. This disclosure relates t...
|
|
WO/2024/100756A1 |
[Problem] To provide a novel agent for preventing and/or treating inflammation in the uterus, fallopian tubes, and ovaries. [Solution] An agent for preventing and/or treating inflammation in the uterus, fallopian tubes, and ovaries that ...
|
|
WO/2024/100919A1 |
Provided is a novel agent which can induce an effect of inhibiting the expression of a pruritus-related gene and is mainly applicable to human skin or the like. The agent for use in the prevention of pruritus according to the present d...
|
|
WO/2024/101402A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing, for example, a cell proliferative disease, the pharmaceutical composition containing as an active ingredient a cyclic compound that selectively inhi...
|
|
WO/2024/102458A1 |
The present disclosure relates to the administration of trazodone or a pharmaceutically acceptable salt thereof to reverse the pharmacological effects of a 5-HT2A receptor agonist in a subject.
|
|
WO/2024/099320A1 |
A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/096818A1 |
The present disclosure relates generally to compositions for enhancing mental wellbeing, particularly compositions from plant extracts for use in calming energizing or enhancing happiness or euphoria in individuals. Methods disclosed inc...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/096418A1 |
The present invention relates to a pharmaceutical or cosmetics composition having anti-inflammatory, anti-pruritic, anti-allergenic, and deodorant effect, the composition comprising composite extract of Lagerstroemia indica and Persicari...
|
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/096124A1 |
The present disclosure provides a microorganism that inhibits oligomer formation of sgA. More specifically, the present disclosure provides a microorganism wherein at least one gene among the curli pili operon gene group, sigma factor ge...
|
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
|
WO/2024/094098A1 |
Provided in the present application are a compound for a delivery system and the use thereof, and an ionizable lipid having a hydrogen bond providing group.
|
